5 Stocks With Monster Returns

This article highlights the 5 Stocks With Monster Returns. For a deeper discussion and an extended list, please see 10 Stocks With Monster Returns.

Photo by Tima Miroshnichenko on Pexels

5. Revolution Medicines Inc. (NASDAQ:RVMD)

Revolution Medicines soared by 54.13 percent week-on-week, with sentiment primarily bolstered by the stellar results of its clinical trial for its pancreatic cancer treatment, while taking heart from bullish recommendations from analysts.

In an updated report, Revolution Medicines Inc. (NASDAQ:RVMD) said that its therapy candidate, Daraxonrasib, recorded a median overall survival of 13.2 months during its late-stage clinical study, as compared with 6.7 months for chemotherapy alone.

“Daraxonrasib, as a targeted medicine, delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy, consistent with earlier findings. These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” Revolution Medicines Inc. (NASDAQ:RVMD) Chairman and CEO Mark Goldsmith said.

Following the results, the company said that it is now “moving with urgency” toward global regulatory submissions, including the filing of a new drug application with the Food and Drug Administration (FDA).

Revolution Medicines Inc. (NASDAQ:RVMD) earned a “strong buy” recommendation from investment firm Raymond James, alongside a 30-percent price target hike of $175, versus $135 previously.

Meanwhile, Bank of America gave a $170 price target, or a 48 percent upgrade from $115, while maintaining a “buy” recommendation.

Jim Cramer, former hedge fund manager and host of the Mad Money show on CNBC, underscored the company’s slashing of death risk by 60 percent.

“That’s rather extraordinary. And … they’re gonna seek FDA approval, Commissioner’s national priority voucher. But what matters here is that Merck, just reportedly, was trying to buy it for $28 to $32 billion, well in excess of what they wanted to buy it, so, you could argue, why did they buy it?”